Who We Are
Our Story
Our Motivation
We established our portfolio using High Throughput Screening assays (HTS), testing a library consisting of over 10,000 known small molecules, we identified hits based on polyglucosan reduction in APBD cells. Our portfolio consists of several innovative small molecules that represent new approaches to correct processes and clinical manifestations of such difficult-to-treat diseases. Beyond APBD, our research efforts are focused on exploring the broader therapeutic potential of our portfolio. We are initially evaluating additional Glycogen Storage Disorders (GSDs), followed by Lysosomal Storage Diseases (LSDs), as well as selected more prevalent conditions where our lead compound may also demonstrate therapeutic benefit.
Our Team
Together with our experienced and esteemed research and physician partners, we are a highly motivated team that aims to efficiently develop treatment solutions to improve patients’ lives.
Board of Directors
Shlomi Schneider
Co-founder, Chairman of the Board
Adi Moreh
Co-founder
David Perlmutter
Itzik Schneider
The Team
Yaniv Glazer BSc MBA
CEO
Yossi Gilgun-Sherki PhD MBA
Head of Product Development
Shira Orel-Ifrah CPA
Finance & Accounting
Doron Shinar PhD
Pre-clinical and toxicology
Danny Fishelovitch PhD
CMC
Uri Sprecher MSc
Project Manager
Advisors and Collaborators
an expert in neurometabolic disorders mainly interested in mechanistic-based development of novel pharmacological therapies
Prof. Or Kakhlon PhD
Hadassah Medical School
a highly experienced cell biologist and drug screening assay developer in the field of personalized medicine and neurodegenerative diseases.
Prof. Miguel Weil PhD
Tel Aviv University
a world leading ABPD specialist whose work pioneered to the identification of the biochemical and molecular basis of the disease. (Jerusalem, Israel).
Prof. Alexander Lossos MD
Hadassah Ein Kerem
Prof. Michio Hirano MD
Columbia University Irving Medical Center (CUIMC)
an award-winning Professor Emeritus of Chemistry (Hebrew University, Jerusalem, Israel); inventor non-aqueous oral solution formulation, for enhanced drug delivery and founder of LDS, Lyotropic Delivery System.
Prof. Nissim Garti PhD, MBA
Lyotropic Delivery Systems Ltd. (LDS)
Clinical study and project coordinator.
Anat Mordechai RN MSc
Hadassah Ein Kerem
Our Name
Golden Heart Flower is the title of a Hebrew short story first published in 1930 by children’s author Shlomo Zalman Ariel. The story follows a child whose mother falls ill, and no one knows how to cure her. An old wise man tells the child that the only way to save her is to find a rare flower with a heart of gold, which grows only in the distant mountains. Once the mother smells it, she will recover. Naturally, the boy finds the flower, brings it to his mother, and everyone lives happily ever after.
Our Partners
APBD Research Foundation – a non-profit health organization dedicated solely to finding the cause and cure for APBD (New York, NY).
Mifneh – an Israeli NPO dedicated to the supporting of patients with APBD and carers, increasing awareness, improving diagnosis, and supporting research in the field.